In fact, LPA and S1P receptors have emerged as novel and fascinating therapeutic targets for several inflammatory CNS diseases, including MS, neuropathic pain, spinal cord injury, cerebral ischemia, traumatic brain injury, hydrocephalus, fetal hypoxia, seizure, hearing loss, Sandhoff disease, and neuropsychiatric disorders [17,20]. The gene discussed is LPA; the disease is myeloid sarcoma.